IMVT250117P32000
- 4.80
- 0.000.00%
Immunovant Newsroom
Guggenheim Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $46
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $45
Immunovant Is Maintained at Buy by B of A Securities
Immunovant Analyst Ratings
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $45
Analysts' Top Healthcare Picks: Annexon Biosciences (ANNX), Immunovant (IMVT)
Wolfe Research Downgrades Immunovant(IMVT.US) to Hold Rating
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $45
Immunovant Is Maintained at Overweight by Wells Fargo
Immunovant Analyst Ratings
Wells Fargo Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $47
H.C. Wainwright Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $48 to $58
Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co.
Immunovant's Promising Pipeline and Strategic Advancements Justify Buy Rating
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Promising Phase 2a Results for Immunovant's Batoclimab Support Buy Rating
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $51
Raymond James Maintains Immunovant(IMVT.US) With Buy Rating, Cuts Target Price to $36
Raymond James Reinstates Outperform on Immunovant, Announces $36 Price Target